Contrarian Profits  Jun 5  Comment 
Brisbane-based growth hormone company Tercica, Inc. (TRCA:NASDAQ) will be acquired by French drugmaker Ipsen SA in a stock deal valued at more than $400 million. Ipsen had an option to buy up to 40% of Tercica through to a 2006 deal. It will...
Pharma's Cutting Edge  Aug 31  Comment 
Yesterday, the U.S. FDA approved Tercica's Increlex (recombinant hIGF-1) as an orphan-status treatment for short stature in children with severe primary IGF-1 deficiency. The press release and Tercica's website can provide details on the drug and...



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki